Replies to post #314 on Optimer Pharmaceuticals, Inc. (OPTR)

[surf1944]

8:03AM Optimer Pharma and AstraZeneca (AZN) collaborate to commercialize fidaxomicin for clostridium difficile infection in Latin America (OPTR) 10.17 : Co announced today the execution of an exclusive agreement with AstraZeneca to commercialize fidaxomicin tablets for the treatment of Clostridium difficile Infection in South America, including Brazil, Central America, Mexico and the Caribbean.

Under the terms of the agreement AZN is responsible for the commercialization of fidaxomicin in the territory covered by the collaboration and OPTR is entitled to receive an up-front payment of $1 mln, up to $3 mln in milestone payments upon first commercial sale in certain countries, and up to $19 mln in other milestone payments contingent on the achievement of sales-related targets for fidaxomicin in the territory. Co is further entitled to receive payments from AstraZeneca that provide a return resulting in a double digit percent of net sales in the territory under a fidaxomicin supply agreement.